Abstract
Tuberculosis (TB) kills more individuals in the world than any other disease, and a threat made direr by the coverage of drug-resistant strains of Mycobacterium tuberculosis (Mtb). Bacillus Calmette–Guérin (BCG) is the single TB vaccine licensed for use in human beings and effectively protects infants and children against severe military and meningeal TB. We applied advanced computational techniques to develop a universal TB vaccine. In the current study, we select the very conserved, experimentally confirmed Mtb antigens, including Rv2608, Rv2684, Rv3804c (Ag85A), and Rv0125 (Mtb32A) to design a novel multi-epitope subunit vaccine. By using the Immune Epitopes Database (IEDB), we predicted different B-cell and T-cell epitopes. An adjuvant (Griselimycin) was also added to vaccine construct to improve its immunogenicity. Bioinformatics tools were used to predict, refined, and validate the 3D structure and then docked with toll-like-receptor (TLR-3) using different servers. The constructed vaccine was used for further processing based on allergenicity, antigenicity, solubility, different physiochemical properties, and molecular docking scores. The in silico immune simulation results showed significant response for immune cells. For successful expression of the vaccine in E. coli, in-silico cloning and codon optimization were performed. This research also sets out a good signal for the design of a peptide-based tuberculosis vaccine. In conclusion, our findings show that the known multi-epitope vaccine may activate humoral and cellular immune responses and maybe a possible tuberculosis vaccine candidate. Therefore, more experimental validations should be exposed to it.
Highlights
Tuberculosis (TB) kills more individuals in the world than any other disease, and a threat made direr by the coverage of drug-resistant strains of Mycobacterium tuberculosis (Mtb)
Rodo et al recommended that the identification of vaccines with distinctive immune response features may increase the probabilities of finding a safe v accine[21] and provided valuable information on the potential production of the Mtb vaccine
Our finding proposed that the selected epitopes from the four Mtb antigens [Rv2608, Rv2684, Rv3804c (Ag85A), and Rv0125 (Mtb32A)] could be used effectively as potential candidates for vaccines and will be applied for future experimental research to eradicate TB
Summary
Tuberculosis (TB) kills more individuals in the world than any other disease, and a threat made direr by the coverage of drug-resistant strains of Mycobacterium tuberculosis (Mtb). Viral vector-based vaccines such as MVA85A and Crucell-Ad35/AERAS-402 will reduce the vaccine’s efficacy before exposure to the vector[14] Live prophylactic vaccines such as recombinant BCG VPM1002 and MTBVAC are p roduced[7,8], and can return to a pathogenic type. H4/IC31 had clinically safe in phase I studies that induced a robust immune response in healthy adults, and BCG vaccinated infants[16]. Some studies had endeavored to evaluate the human T cell immune responses to multiple Mtb subunit vaccines e mpirically[20,21] and using data from clinical trials, respectively[22,23,24]. Rodo et al recommended that the identification of vaccines with distinctive immune response features may increase the probabilities of finding a safe v accine[21] and provided valuable information on the potential production of the Mtb vaccine
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
